AYTU BIOPHARMA Reports a Net Loss of $17.1 Million for the Year Ended June 30, 2023

AYTU BIOPHARMA, a leading pharmaceutical company, has released its financial results for the year ended June 30, 2023. Despite strong annual revenue of $107.4 million, the company reported a net loss of $17.1 million during the period.

Financial Performance

In terms of financial performance, AYTU BIOPHARMA experienced a gross profit of $66.6 million, reflecting a significant increase compared to the previous year's gross profit of $52.3 million. However, operating expenses amounted to $83.7 million, leading to a loss from operations of $17.1 million. The company's other income, including gain on derivative warrant liability, amounted to $14 thousand, resulting in a net loss before income tax of $17.1 million.